LYEL
Lyell Immunopharma, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website lyell.com
- Employees(FY) 274
- ISIN US55083R1041
Performance
+2.24%
1W
+13.69%
1M
+47.31%
3M
+46.52%
6M
+41.24%
YTD
+2.62%
1Y
Profile
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
Investment Analysis Report: LYEL
Overview:
LYEL is a company operating in the Health Technology sector, specifically in the Biotechnology industry. The company has a market capitalization of $468,476,284. In this report, we will conduct a detailed analysis of LYEL's financial health, earnings and revenue growth, profitability, operating margin, ...
Technical Analysis of LYEL 2024-05-10
Overview:
In analyzing the technical indicators for LYEL stock over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and recommendations for potent...
Recent News & Updates
- 2024-05-07 16:05
- 2024-05-07 06:37
- 2024-05-07 04:05
- 2024-05-06 13:34
Lyell Immunopharma Shares Rise After Q1 Net Loss Narrows(MT Newswires)
- 2024-05-06 10:53
- 2024-05-06 08:23
Lyell Immunopharma: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-06 08:00
- 2024-05-05 20:00
- 2024-03-18 22:00
- 2024-03-17 09:47
- 2024-03-07 12:00
- 2024-03-06 23:00
- 2024-03-05 16:30
- 2024-03-05 03:30
- 2024-02-28 16:44
- 2024-02-28 16:05
- 2024-02-28 03:05
- 2024-02-26 16:05
- 2024-02-26 03:05
- 2024-01-29 09:08
- 2024-01-04 09:04
- 2024-01-03 16:05
- 2024-01-03 03:05
- 2023-12-19 08:56
- 2023-11-09 16:05
- 2023-11-09 03:05
- 2023-11-07 16:33
Lyell Immunopharma: Q3 Earnings Snapshot(Associated Press Finance)
- 2023-11-07 16:05
- 2023-11-07 03:05
- 2023-10-31 09:00
Page 1 of 4
previousnext